| |
 |
 |  |
|
|
Romark's commitment to research is deeply rooted in a tradition of drug discovery and development tied closely
to its founder, Jean-François Rossignol. Dr. Rossignol, a Sorbonne graduate, was trained as a chemist and
physician, leading to an accomplished career as a research scientist.
In 1993, Rossignol and investor/partner Marc Ayers co-founded Romark Laboratories, L.C., to develop
Rossignol's invention, nitazoxanide, as a treatment for Cryptosporidium infection and to discover and
develop other new small molecule drugs.
In 2002, Alinia® (nitazoxanide) suspension was approved by the FDA for treating diarrhea caused by
Cryptosporidium parvum and Giardia lamblia in children. Alinia® tablets were approved by the FDA in July 2004.
In 2005, the company began developing Alinia® for other therapeutic indications, including Clostridium
difficile-associated disease, rotavirus gastroenteritis and chronic Hepatitis C.
Between 2005 and 2006, Romark's drug discovery program led to the characterization of a new class of
drugs called the thiazolides and identification of new drug candidates for treating Hepatitis B,
and Hepatitis C.
In 2006, Romark initiated a collaborative research program with Stanford University to advance its drug discovery and development efforts in virology and liver diseases.
Selected publications
- Amadi, B, Mwiya, M, Musuku, J, Watuka, A, Sianongo, S, Ayoub, A & Kelly, P. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet. 2002;360:1375-1380.
- Rossignol, JF, Kabil, SM, Said, M, Samir, H, Younis, A. Effect of Nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. Clinical Gastroenterology & Hepatology. 2005;3:987-991.
- Rossignol, JF, Abou Zekry, M, Hussein, A & Santoro, MG. Effect of nitazoxanide in treating rotavirus diarrhea: a randomized, double-blind, placebo-controlled trial. Lancet. 2006;368:124-29.
- Rossignol, JF, El-Gohary, Yehia M. Nitazoxanide in treatment of viral gastroenteris: a randomized, double-blind, placebo-controlled clinical trial. Alimentary Pharmacology & Therapeutics. 2006;24:1423-30.
- Musher, DM, Logan, N, Hamill, RJ, DuPont, HL, Lentnek, A, Gupta, A & Rossignol, JF. Nitazoxanide in the treatment of Clostridium difficile-associated diseases. Clinical Infectious Diseases. 2006;43:421-7.
|
 |
 |
|
|
